Rosetta Genomics, Ltd./ IL0011026494 /
| 8/27/2024 9:39:28 PM | Chg. - | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 0.0000USD | - | 167 Turnover: .0002 |
-Bid Size: - | -Ask Size: - | 0.0000 | 0.0000 |
GlobeNewswire
8/6/2019
Predictive Technology Group Names Industry Veteran Dr. E. Robert Wassman Co-Laboratory Director of P...
GlobeNewswire
3/19/2019
Interpace Diagnostics Group Reports Full Year and Fourth Quarter 2018 Financial Results
GlobeNewswire
11/27/2018
RNAi Technologies: Worldwide Market Analysis 2015-2018 and Outlook to 2027 by Therapeutics, Applicat...
GlobeNewswire
10/15/2018
Global Personalized Medicine Market to 2024: Personalized Cancer Therapy Gets a Boost from Patient-D...
GlobeNewswire
8/15/2018
Interpace Diagnostics Acquires Select Assets of Rosetta Genomics Out of Bankruptcy
GlobeNewswire
8/9/2018
Interpace Diagnostics Group Reports Second Quarter 2018 Financial Results, Business Progress and Rec...
GlobeNewswire
7/18/2018
Delisting of Securities of Rosetta Genomics Ltd., ConvergeOne Holdings, Inc. (Warrant Only), FC Glob...
GlobeNewswire
5/23/2018
Global Personalized Medicines Strategic Business Report 2018: Annual Estimates & Forecasts 2016-2024
GlobeNewswire
3/8/2018
2018 $879 Million Clinical Genomics Market By Test Type, Software, Method and End User - Global Fore...
GlobeNewswire
10/12/2017
Global MicroRNA Market to Reach US$ 666.7 Mn by 2025 – Persistence Market Research
GlobeNewswire
10/11/2017
Worldwide Liquid Biopsy Market 2017-2021 by Analyte, Application - Screening/Drug Monitoring/Diagnos...
GlobeNewswire
9/15/2017
Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Others. 2017-2020 Including Screenin...
GlobeNewswire
9/6/2017
Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel
